In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.
Bottom Line: Previous studies have indicated that heparanase (Hpa) might represent a candidate universal tumor-associated antigen.The results showed that multi-epitope vaccines Hpa525 + 277 + 405 + 16 and Hpa8 + 310 + 315 + 363 induced higher Hpa-specific lysis of various cancer cells from different tissues in a HLA-A2-restricted and heparanase-specific manner compared with the single epitope vaccines Hpa525, Hpa277, Hpa405, Hpa16, Hpa8, Hpa310, Hpa315 and Hpa363, both in vitro and ex vivo.Therefore, the present study provides theoretical evidence for the use of heparanase multi-epitope vaccines for clinical application.
Affiliation: Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing, China; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.Show MeSH
Related in: MedlinePlus
Mentions: Heparanase is expressed in immunologically competent cells, natural killer cells and inflammatory cells such as neutrophils, granulocytes and activated T and B cells.25 Theoretically, immunotherapy targeting heparanase might have side-effects on the immune system. To investigate the effect of heparanase-specific CTL on immunologically activated lymphocytes, CTL induced by heparanase-specific peptides were also used to lyse autologous lymphocytes and DC. The results indicate that multi-epitope vaccines and their corresponding single peptides from heparanase did not lyse autologous lymphocytes or DC in vitro or ex vivo (Fig.5).
Affiliation: Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing, China; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.